Kondo, S., Tajimi, M., Funai, T., Inoue, K., Asou, H., Ranka, V. K., . . . Doi, T. (2020). Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer. Invest New Drugs.

Kondo, Shunsuke, Masaomi Tajimi, Tomohiko Funai, Koichi Inoue, Hiroya Asou, Vinay Kumar Ranka, Volker Wacheck, und Toshihiko Doi. "Phase 1 Dose-escalation Study of a Novel Oral PI3K/mTOR Dual Inhibitor, LY3023414, in Patients With Cancer." Invest New Drugs 2020.

Kondo, Shunsuke, et al. "Phase 1 Dose-escalation Study of a Novel Oral PI3K/mTOR Dual Inhibitor, LY3023414, in Patients With Cancer." Invest New Drugs 2020.